A Depression Study Examining the Effects of Lumateperone in Treatment-Resistant Depression
Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of
Patients with Major Depressive Disorder
Purpose
Depression is one of the most common mental health issues worldwide. Many people with major depressive disorder (MDD) take antidepressant medications that do not provide enough of a response to ease their depressive symptoms.
The primary objective of this study is to evaluate the benefit of Lumateperone 42 mg administered once daily compared with placebo as adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) who have an inadequate response to ongoing ADT.
Could this study be right for you?
You may be able to take part if you:
• are 18–65 years of age
• have a confirmed diagnosis of Major Depressive Disorder (MDD)
• feel that your current antidepressant medication is not working well
• Has tried 2 or more antidepressant medication in the current episode of depression
Other criteria will need to be met to confirm your eligibility for this study.